ArticleCell reports. Medicine2025

First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors.

Xiao-Li Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.